These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 8633078)
1. Viral dynamics in hepatitis B virus infection. Nowak MA; Bonhoeffer S; Hill AM; Boehme R; Thomas HC; McDade H Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4398-402. PubMed ID: 8633078 [TBL] [Abstract][Full Text] [Related]
2. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection. Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067 [TBL] [Abstract][Full Text] [Related]
3. A preliminary trial of lamivudine for chronic hepatitis B infection. Dienstag JL; Perrillo RP; Schiff ER; Bartholomew M; Vicary C; Rubin M N Engl J Med; 1995 Dec; 333(25):1657-61. PubMed ID: 7477217 [TBL] [Abstract][Full Text] [Related]
4. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Benhamou Y; Dohin E; Lunel-Fabiani F; Poynard T; Huraux JM; Katlama C; Opolon P; Gentilini M Lancet; 1995 Feb; 345(8946):396-7. PubMed ID: 7845151 [No Abstract] [Full Text] [Related]
6. Lamivudine useful against hepatitis B-HIV co-infection. Prescott LM J Int Assoc Physicians AIDS Care; 1995 Jun; 1(5):34. PubMed ID: 11362610 [TBL] [Abstract][Full Text] [Related]
7. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P Ann Intern Med; 1996 Nov; 125(9):705-12. PubMed ID: 8929003 [TBL] [Abstract][Full Text] [Related]
8. Dynamics of hepatitis B virus infection in vivo. Zeuzem S; de Man RA; Honkoop P; Roth WK; Schalm SW; Schmidt JM J Hepatol; 1997 Sep; 27(3):431-6. PubMed ID: 9314118 [TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. Alvarez-Uria G; Ratcliffe L; Vilar J HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695 [TBL] [Abstract][Full Text] [Related]
11. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen. Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084 [TBL] [Abstract][Full Text] [Related]
12. Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation. Panos GZ; Lampropoulos KM; Angelousi AG; Charatsis GG; Falagas ME J Clin Gastroenterol; 2007 Feb; 41(2):222-3. PubMed ID: 17245225 [No Abstract] [Full Text] [Related]
13. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients]. Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144 [TBL] [Abstract][Full Text] [Related]
14. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count). Haverkamp M; Smit M; Weersink A; Boucher CA; Hoepelman AI AIDS; 2003 Jul; 17(10):1572-4. PubMed ID: 12824802 [TBL] [Abstract][Full Text] [Related]
15. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172 [TBL] [Abstract][Full Text] [Related]
16. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR; Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101 [TBL] [Abstract][Full Text] [Related]
17. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis B reactivation after lamivudine. Honkoop P; de Man RA; Heijtink RA; Schalm SW Lancet; 1995 Oct; 346(8983):1156-7. PubMed ID: 7475613 [No Abstract] [Full Text] [Related]
20. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]